224 related articles for article (PubMed ID: 22211714)
21. Colon delivery efficiencies of intestinal pressure-controlled colon delivery capsules prepared by a coating machine in human subjects.
Hu Z; Mawatari S; Shimokawa T; Kimura G; Yoshikawa Y; Shibata N; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1187-93. PubMed ID: 11092562
[TBL] [Abstract][Full Text] [Related]
22. Mucoadhesive platforms for targeted delivery to the colon.
Varum FJ; Veiga F; Sousa JS; Basit AW
Int J Pharm; 2011 Nov; 420(1):11-9. PubMed ID: 21856393
[TBL] [Abstract][Full Text] [Related]
23. Development and in-vitro evaluation of a colon-specific controlled release drug delivery system.
Talukder RM; Fassihi R
J Pharm Pharmacol; 2008 Oct; 60(10):1297-303. PubMed ID: 18812022
[TBL] [Abstract][Full Text] [Related]
24. Development and evaluation of chitosan and chitosan/Kollicoat® Smartseal 30 D film-coated tablets for colon targeting.
Drechsler M; Garbacz G; Thomann R; Schubert R
Eur J Pharm Biopharm; 2014 Nov; 88(3):807-15. PubMed ID: 25301294
[TBL] [Abstract][Full Text] [Related]
25. Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting.
Fukui E; Miyamura N; Uemura K; Kobayashi M
Int J Pharm; 2000 Aug; 204(1-2):7-15. PubMed ID: 11011980
[TBL] [Abstract][Full Text] [Related]
26. Colon-specific drug delivery using ethylcellulose and chitosan in the coat of compression-coated tablets.
Omwancha W; Kouba C; Yelamanchili S; Neau SH
Drug Dev Ind Pharm; 2011 Aug; 37(8):945-53. PubMed ID: 21417614
[TBL] [Abstract][Full Text] [Related]
27. Design of experiment approach for formulating multi-unit colon-targeted drug delivery system: in vitro and in vivo studies.
Shah N; Sharma OP; Mehta T; Amin A
Drug Dev Ind Pharm; 2016; 42(5):825-35. PubMed ID: 27019195
[TBL] [Abstract][Full Text] [Related]
28. Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment.
Bose A; Elyagoby A; Wong TW
Int J Pharm; 2014 Jul; 468(1-2):178-86. PubMed ID: 24709212
[TBL] [Abstract][Full Text] [Related]
29. Design and gamma scintigraphic evaluation of colon specific pectin-EC pellets of secnidazole prepared by powder layering technology.
Majumdar S; Roy S; Ghosh B
Pharmazie; 2011 Nov; 66(11):843-8. PubMed ID: 22204129
[TBL] [Abstract][Full Text] [Related]
30. Chitosan-based controlled porosity osmotic pump for colon-specific delivery system: screening of formulation variables and in vitro investigation.
Liu H; Yang XG; Nie SF; Wei LL; Zhou LL; Liu H; Tang R; Pan WS
Int J Pharm; 2007 Mar; 332(1-2):115-24. PubMed ID: 17052871
[TBL] [Abstract][Full Text] [Related]
31. Coated chitosan pellets containing rutin intended for the treatment of inflammatory bowel disease: in vitro characteristics and in vivo evaluation.
Rabišková M; Bautzová T; Gajdziok J; Dvořáčková K; Lamprecht A; Pellequer Y; Spilková J
Int J Pharm; 2012 Jan; 422(1-2):151-9. PubMed ID: 22079717
[TBL] [Abstract][Full Text] [Related]
32. Development and in vitro evaluation of mesalamine delayed release pellets and tableted reservoir-type pellets.
Bendas ER; Christensen JM; Ayres JW
Drug Dev Ind Pharm; 2010 Apr; 36(4):393-404. PubMed ID: 19740039
[TBL] [Abstract][Full Text] [Related]
33. New co-processed MCC-based excipient for fast release of low solubility drugs from pellets prepared by extrusion-spheronization.
Goyanes A; Martínez-Pacheco R
Drug Dev Ind Pharm; 2015 Mar; 41(3):362-8. PubMed ID: 24279425
[TBL] [Abstract][Full Text] [Related]
34. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery.
Akhgari A; Afrasiabi Garekani H; Sadeghi F; Azimaie M
Int J Pharm; 2005 Nov; 305(1-2):22-30. PubMed ID: 16236475
[TBL] [Abstract][Full Text] [Related]
35. Interdiction of hypoglycemia in diabetic children by multiparticulate dosage form with controlled glucose release.
Franc A; Sabadková D; Neumann D; Pavloková S; Kopecká P; Muselík J
Pharm Dev Technol; 2016 Nov; 21(7):867-874. PubMed ID: 26334252
[TBL] [Abstract][Full Text] [Related]
36. An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man.
McConnell EL; Short MD; Basit AW
J Control Release; 2008 Sep; 130(2):154-60. PubMed ID: 18639950
[TBL] [Abstract][Full Text] [Related]
37. Controlled Release Oral Delivery of Apigenin Containing Pellets with Antioxidant Activity.
Pápay ZE; Kállai-Szabó N; Balogh E; Ludányi K; Klebovich I; Antal I
Curr Drug Deliv; 2017; 14(1):145-154. PubMed ID: 27264725
[TBL] [Abstract][Full Text] [Related]
38. New targeted-colon delivery system: in vitro and in vivo evaluation using X-ray imaging.
Yassin AE; Alsarra IA; Alanazi FK; Al-Mohizea AM; Al-Robayan AA; Al-Obeed OA
J Drug Target; 2010 Jan; 18(1):59-66. PubMed ID: 19653868
[TBL] [Abstract][Full Text] [Related]
39. Coated hard capsules as the pH-dependent drug transport systems to ileo-colonic compartment.
Dvořáčková K; Rabišková M; Muselík J; Gajdziok J; Bajerová M
Drug Dev Ind Pharm; 2011 Oct; 37(10):1131-40. PubMed ID: 21417619
[TBL] [Abstract][Full Text] [Related]
40. Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon.
Bristol A; Hubert S; Hofmann F; Baer H
Int J Pharm; 2017 Dec; 534(1-2):25-34. PubMed ID: 28986322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
